Wegovy 7.2mg Reviews: What People Are Reporting and What the Trials Show

The decision most people are actually facing at this dose

Reaching 7.2mg is not something that happens at week two. By the time a prescriber is discussing this dose with you, you've already spent months on lower strengths, your body has adjusted to semaglutide, and the conversation shifts from 'can you tolerate this medicine' to 'is there more clinical benefit available'. That is the decision this page is written to help you think through.

Most people who leave reviews about Wegovy 7.2mg are doing so after a substantial journey. They are not comparing it to doing nothing, they're comparing it to where they were at 2.4mg. That context matters when you read accounts online. A reviewer who says '7.2mg changed everything' has usually plateaued at a lower dose first. One who found the side-effect profile harder is often someone whose GI tolerance was already stretched at 2.4mg.

If you want to understand the earlier rungs before reaching this point, the 2.4mg patient experience is covered separately, and the full Wegovy dose schedule explains how titration works in practice. The pattern of reported experiences at 7.2mg makes a lot more sense once you know where it sits in the sequence.

What the clinical trial data says, and what it doesn't

The MHRA's approval of Wegovy 7.2mg rested on trial evidence showing approximately 20.7% average weight loss over 72 weeks, compared with the roughly 15% average seen with the 2.4mg dose in the STEP 1 study, published in the New England Journal of Medicine. That is a substantial step up, and it brings semaglutide closer to the results seen with tirzepatide at its highest dose, something worth knowing if you're comparing options.

What trial data does not show you is how any individual person will respond. Averages mask wide variation. Some participants in the 7.2mg trials lost considerably more than 20%; others lost less. Weight loss in these trials was also achieved alongside a reduced-calorie diet and increased physical activity, the medicine is one part of the picture, not all of it.

The MHRA's announcement of the dedicated 7.2mg pen (14 April 2026) confirmed the device specifics: one pre-set weekly injection, an auto-dosing mechanism, a built-in covered needle that locks after use. That design change from three 2.4mg pens weekly to a single injection is consistently mentioned in early patient accounts as a practical improvement, fewer injection events per week, less room for dosing error.

Side effects at 7.2mg broadly mirror the GI profile seen across the semaglutide dose range: nausea, loose stools, constipation, indigestion and fatigue are the most commonly reported. The NHS semaglutide information page sets out the full side-effect profile clearly. What reviewers often add is that GI effects at 7.2mg can be more pronounced than at lower doses, particularly in the first week or two after the increase, manageable for most, but worth anticipating. Staying well hydrated and eating smaller, lower-fat meals during that adjustment window is advice prescribers give routinely.

Who reaches 7.2mg, and what eligibility actually means at this level

Eligibility for the 7.2mg pen is narrower than for Wegovy generally. The MHRA licence is for adults with a BMI of 30 or above, it does not extend to the 27–29.9 range with a weight-related condition in the way the lower-dose licence does, and it is not approved for the cardiovascular risk-reduction indication.

In practice, reaching 7.2mg also requires that you've tolerated the titration steps below it. A prescriber won't jump doses; each monthly increase is a clinical decision based on how you're doing. Many people settle at 1.7mg or 2.4mg and do well there, the 7.2mg dose exists for those for whom a higher dose is clinically justified, not as a default endpoint. The Wegovy overview covers the eligibility picture in full if you're working out whether the medicine is the right fit before considering which dose.

For a clear read on what treatment might cost at this level, the Wegovy cost page covers pricing context honestly, including what a legitimate private prescription actually includes beyond the headline figure.

How to read 'reviews' for a prescription medicine

This is the thing our prescribers find themselves explaining most often: online reviews of prescription medicines are self-selected in ways that skew both directions. People who've had a striking result and people who've had a difficult time are both more likely to post than someone who has had a steady, unremarkable experience, which is, in fact, the most common one.

Forum threads, social media posts and aggregated ratings are useful for knowing what questions to ask, not for predicting your own outcome. A review that says '7.2mg made me vomit every week' tells you that GI effects at this dose can be significant for some people, and you should discuss your own GI history with your prescriber before moving to this strength. It doesn't tell you that will happen to you. Equally, if you're curious how people got on at the very beginning of the journey, the wegovy 0.25 reviews from people starting out show how different that early experience can feel compared with where most 7.2mg users are now. A review saying '7.2mg was the only thing that moved the scale' doesn't mean lower doses won't work for you, and reading what people reported at the 1mg stage is a useful reminder of how much the picture can shift as the dose increases.

If you're considering starting or progressing with Wegovy and want to understand the full picture from a clinical team rather than a comment section, the weight loss treatment overview is a good starting point. At nume (sorry, at our pharmacy) every consultation is personally reviewed by a GPhC-registered prescriber on the same day, so you get an individual assessment rather than a generalised plan. Check your eligibility by starting a free consultation, and a prescriber will look at your specific circumstances, not just your BMI.